文献速递认知障碍与痴呆脑血管病

显性遗传性阿尔茨海默病中脑微出血的纵向累积

Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
PubMed 文献 · Neurology · 2021-01-25

本研究纵向评估了显性遗传性阿尔茨海默病(DIAD)家族中脑微出血(CMHs)的临床风险。310名突变携带者和201名非携带者接受包括梯度回波MRI在内的神经影像和临床评估。结果显示8%携带者和3%非携带者出现CMHs,且CMHs与痴呆严重程度相关;2个及以上CMHs预测后续每年新增8.95±10.04个CMHs。

要点

  • DIAD突变携带者中CMHs发生率(8%)高于非携带者(3%),主要位于脑叶。
  • 携带CMHs者年龄更大、舒张压更高、Hachinski评分更高,临床和认知损害更重。
  • 2个及以上CMHs预测后续每年新增8.95±10.04个CMHs,提示高出血风险。

核心结论

  • CMHs是DIAD疾病过程的一部分,且与痴呆显著相关。
  • 在抗淀粉样蛋白治疗试验中,难以区分自然发生的CMHs与药物相关ARIA-H。

研究设计与样本

  • 纵向观察性研究,纳入310名DIAD突变携带者和201名非携带者。
  • 采用梯度回波MRI序列检测CMHs,并进行神经心理和临床评估。

主要发现

  • 3%非携带者和8%携带者出现CMHs,主要位于脑叶。
  • 携带CMHs者年龄更大、舒张压更高、Hachinski缺血评分更高,临床、认知和运动损害更重。
  • APOE ε4状态与CMHs的患病率或发病率无关。
  • prevalent或incident CMHs预测临床痴呆评定量表(CDR)变化更快,但不预测复合认知指标、皮层厚度、海马体积或白质病变的变化。
  • 2个及以上CMHs与后续每年新增8.95±10.04个CMHs显著相关。

临床怎么用

  • 在DIAD患者中应监测CMHs,尤其是已有2个及以上CMHs者,因其后续出血风险高。
  • 在抗淀粉样蛋白治疗试验中,需注意区分自然发生的CMHs与药物相关ARIA-H。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the inherent clinical risks associated with the presence of cerebral microhemorrhages (CMHs) or cerebral microbleeds and characterize individuals at high risk for developing hemorrhagic amyloid-related imaging abnormality (ARIA-H), we longitudinally evaluated families with dominantly inherited Alzheimer disease (DIAD). METHODS: Mutation carriers (n = 310) and noncarriers (n = 201) underwent neuroimaging, including gradient echo MRI sequences to detect CMHs, and neuropsychological and clinical assessments. Cross-sectional and longitudinal analyses evaluated relationships between CMHs and neuroimaging and clinical markers of disease. RESULTS: Three percent of noncarriers and 8% of carriers developed CMHs primarily located in lobar areas. Carriers with CMHs were older, had higher diastolic blood pressure and Hachinski ischemic scores, and more clinical, cognitive, and motor impairments than those without CMHs. APOE ε4 status was not associated with the prevalence or incidence of CMHs. Prevalent or incident CMHs predicted faster change in Clinical Dementia Rating although not composite cognitive measure, cortical thickness, hippocampal volume, or white matter lesions. Critically, the presence of 2 or more CMHs was associated with a significant risk for development of additional CMHs over time (8.95 ± 10.04 per year). CONCLUSION: Our study highlights factors associated with the development of CMHs in individuals with DIAD. CMHs are a part of the underlying disease process in DIAD and are significantly associated with dementia. This highlights that in participants in treatment trials exposed to drugs, which carry the risk of ARIA-H as a complication, it may be challenging to separate natural incidence of CMHs from drug-related CMHs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Joseph-Mathurin N, Wang G, Kantarci K, et al. Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology. 2021. PMID: 33495373. doi:10.1212/WNL.0000000000011542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。